Through a rich blend of leadership roles in industry, government, and academic sectors, Dr. William Rice has accrued more than 25 years of know-how and forged a diverse set of skills, including executive, operational, business development, financial, product research, and development. Before Aptose, Dr. Rice served as the president, chief executive officer and chairman of the board of Cylene Pharmaceuticals, Inc. In that role he led the company’s strategic, financing, and business development activities, resulting in the development and sale of small molecule therapeutic programs designed to exploit CK2-mediated pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Before Cylene, Dr. Rice was the founder, president, chief executive officer, and director of Achillion Pharmaceuticals, Inc. He also served as a senior scientist and head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine. Throughout his career, Dr. Rice has identified multiple new molecular drug targets, delivered multiple first-in-class drugs to the clinic, and published peer-reviewed findings in Science, Nature, Cancer Cell, Nature Medicine, Proceedings of the National Academy of Sciences, among other prestigious journals. Dr. Rice holds a Doctor of Philosophy in Biochemistry from Emory University and was a postdoctoral trainee in the Department of Internal Medicine at the University of Michigan Medical Center.
What is William G. Rice's net worth?
The estimated net worth of William G. Rice is at least $29,543.52 as of September 19th, 2022. Dr. Rice owns 24,216 shares of Aptose Biosciences stock worth more than $29,544 as of April 26th. This net worth estimate does not reflect any other assets that Dr. Rice may own. Learn More about William G. Rice's net worth.
How old is William G. Rice?
How do I contact William G. Rice?
Has William G. Rice been buying or selling shares of Aptose Biosciences?
William G. Rice has not been actively trading shares of Aptose Biosciences during the past quarter. Most recently, on Monday, September 19th, William G. Rice bought 666 shares of Aptose Biosciences stock. The stock was acquired at an average cost of $10.20 per share, with a total value of $6,793.20. Following the completion of the transaction, the chief executive officer now directly owns 24,216 shares of the company's stock, valued at $247,003.20. Learn More on William G. Rice's trading history.
Who are Aptose Biosciences' active insiders?
Are insiders buying or selling shares of Aptose Biosciences?
In the last twelve months, Aptose Biosciences insiders bought shares 1 times. They purchased a total of 17,000 shares worth more than $53,380.00. The most recent insider tranaction occured on September, 22nd when Director Bernd R Seizinger bought 17,000 shares worth more than $53,380.00. Insiders at Aptose Biosciences own 9.5% of the company.
Learn More about insider trades at Aptose Biosciences. Information on this page was last updated on 9/22/2023.